Iovance Biotherapeutics - Профиль
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
Акционеры
| Название |
Доля (%) |
| Freefloat | 88,52 |
| The Vanguard Group, Inc. | 7,76 |
| Perceptive Advisors LLC | 6,44 |
| Wellington Management Co. LLP | 6,10 |
| Avoro Capital Advisor LLC | 5,52 |
| Quogue Capital LLC | 4,50 |
| Franklin Advisers, Inc. | 3,67 |
| Xtrackers SICAV - S&P 500 Swap UCITS ETF | 2,39 |
| Nikko AM Global Umbrella Fund - ARK Disruptive Innovation | 2,03 |
| Armistice Capital LLC | 1,91 |
| Frazier Management LLC | 1,11 |
| Norges Bank (13F) | 0,83 |
| Lord, Abbett & Co. LLC | 0,70 |
| Jeffrey Robert Jay, MD | 0,59 |